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Abstract 
Chiral sulfoximines have applications as transition-state mimicking enzyme inhibitors, as 
peptide isosteres and as chiral auxiliaries in synthesis. To access the required O-protected 4-
(arylsulfonimidoyl)butane-1,2,3-triols, 4S,5S-di(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane 
(prepared from diethyl R,R-tartrate) was converted into its monobenzyl ether. Mitsunobu-like 
coupling with thiophenols gave 4S,5R-4-(benzyloxymethyl)-2,2-dimethyl-5-(arylthiomethyl)-
1,3-dioxolanes. Sulfoxidation and S-imination (trifluoroacetamide, iodosobenzene diacetate, 
rhodium acetate) proceeded without stereoselectivity, giving inseparable diastereomeric 
mixtures of 4S,5R,S(±)-4-(benzyloxymethyl)-2,2-dimethyl-5-(N-(trifluoroacetyl)arylsulfon-
imidoylmethyl)-1,3-dioxolanes. Removal of the trifluoroacetyl protection allowed chromato-
graphic separation of the diastereomeric 4S,5R,S(±)-4-(benzyloxymethyl)-2,2-dimethyl-5-
(arylsulfonimidoylmethyl)-1,3-dioxolanes. The configurations at sulfur were determined by 
X-ray crystallography and some analysis of the solution and solid-state conformations was 
carried out. The resulting O-protected 4-(arylsulfonimidoyl)butane-1,2,3-triols are of use in 
developing enzyme inhibitors. 
Keywords: Sulfoximine, butanetriol, X-ray crystallography, conformation, diastereoisomer. 
1. Introduction 
Sulfoximines have attracted chemical and biological attention since the discovery of αS,S(S)-
methionine sulfoximine 1 (Figure 1) as the toxic agent in agenised flour in the 1950s.1 This 
compound inhibits glutamine synthetase,2  the enzyme responsible for the formation of Gln 
from Glu and ammonia, and γ-glutamylcysteine 
synthetase,3 which catalyses the first step in the 
biosynthesis of glutathione. Later studies showed that 
the homologue, αS,S(S)-buthionine sulfoximine 2 is a 
more potent and selective inhibitor of γ-glutamylcys-
teine synthetase.4,5 In 1 and 2, the tetrahedral sulfox-
imine unit is acting as a mimic of the transition state or 
intermediate of the enzyme-catalysed process.2-4 Sulf-
oximines are configurationally stable. More recently, 
sulfoximines have been used in asymmetric synthesis 
as chiral ligands or chiral auxiliaries,6-8 as peptido-
mimetics (e.g. 3, Figure 1)9,10 and as transition-state 
mimics in the design of other enzyme inhibitors.11 As part of our programme of design and 
synthesis of selective enzyme inhibitors,12-14 we required the individual diastereoisomers of 
O-protected 2S,3R-4-(arylsulfonimidoyl)butane-1,2,3-triols with different configurations at 
sulfur. 
2. Synthesis 
The synthetic approach to the target O-protected sulfoximine triols is shown in Scheme 1. We 
proposed that the four-carbon unit bearing the two carbon chiral centres could be introduced 
from a precursor available from the chiral pool. The sulfoximine chiral centre could be 
created by diastereoselective sulfoxidation of the intermediate aryl sulfide, followed by 
imination or, less efficently, by generation of a mixture of diastereoisomeric sulfides and 
selective imination of one diastereoisomer. 
Diethyl R,R-tartrate 4 contains the required secondary alcohols in the configurations corres-
ponding to those in the synthetic targets 12 and 13. These were protected as the acetonide by 
ketal exchange with 2,2-dimethoxypropane; the esters (mixed methyl and ethyl esters) were 
then reduced with lithium aluminium hydride to give the C2-symmetric S,S-diol 5. Desymmet-
risation by monobenzylation with sodium hydride and benzyl bromide in DMF afforded 7 in 
71% yield, which could be readily separated from the small quantity of dibenzyl ether 6 pro-
duced. The next step involved displacement of the primary OH with (substituted)thiophenols, 
for which it would be necessary to convert it into a good leaving group. Treatment of 7 with 
tetrabromomethane and triphenylphosphine efficiently converted it into the bromo compound 
Figure 1.  Structures of αS,S(S)-meth-
ionine sulfoximine 1, αS,S(S)-buth-
ionine sulfoximine 2 and a peptido-
mimetic 3 containing a sulfoximine. 
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8. Interestingly, this primary alkyl halide could not be displaced with phenylthiolate anions 
under a variety of forcing conditions; study of the required angle of approach of the nucleo-
phile to the electrophilic CH2 in 8 in an SN2 process indicated that steric crowding between 
the dioxolane and the incoming aromatic ring may preclude reaction. In contrast, displace-
ment of the primary OH of with the arylthio nucleophiles was achieved directly from 6 under 
Mitsunobu conditions (arylthiol, tributylphosphine, 1,1’-(azodicarbonyl)dipiperidine) to give 
the sulfides 9a and 9b in good yields. 
At this point, it had been anticipated that the chirality of the sulfides 9 could be exploited to 
drive the sulfoxidation in a diastereoselective manner. However, no conditions could be found 
to achieve this diastereoselection, so 9a was treated with 3-chloroperoxybenzoic acid to give a 
high yield of the sulfoxides 10a as an inseparable 1:1 mixture of diastereoisomers. Similar 
reaction of the bromophenylsulfide 9b gave the corresponding sulfoxides 10b, also as an in-
separable equimolar mixture. A variety of reagents and conditions have been used to generate 
sulfoximines from sulfoxides, including sodium azide / hot conc. sulfuric acid15 and O-(2,4,6-
trimethylbenzenesulfonyl)hydroxylamine16 but many are incompatible with the protecting 
Scheme 1. Synthesis of the diastereoisomers of sulfoximines 13. Reagents and conditions: i, (MeO)2CMe2, 
TsOH, CH2Cl2, ∆; ii, LiAlH4, THF, ∆; iii, NaH, BnBr, DMF, 0°C; iv, Ph3P, CBr4, THF; v, PhSH, various bases, 
various conditions; vi, PhSH/3-BrC6H4SH, Bu3P, 1,1’-(azodicarbonyl)dipiperidine, THF, )))); vii, 3-ClPhCO3H, 
CH2Cl2, -78°C; viii, CF3CONH2, MgO, Rh2(OAc)4, PhI(OAc)2, CH2Cl2; ix, NH3, H2O, MeOH; x, HCl, H2O, 
MeOH. 
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groups used here. Okamura and Bolm have devel-
oped a very mild sulfoximination in which 
PhI=NCOCF3 is generated in situ from iodoso-
benzene diacetate and trifluoroacetamide and Rh-
catalysed transimination converts sulfoxides into 
N-trifluoroacetyl sulfoximines.17 Application of 
this method to the mixture of diastereoisomeric Ph-
unsubstituted sulfoxides 10a gave a mixture of 
diastereoisomers of the N-trifluoroacetylsulfox-
imine 11a; the ratio of the diastereoisomers shifted 
from 1:1 in 10a to 3:2 in 11a, indicating that one 
diastereoisomer had reacted slightly more 
efficiently, but the isomers again could not be 
separated. In parallel, the bromophenylsulfoxides 
10b were converted into the inseparable N-tri-
fluoroacetyl sulfoximines 11b with no change in the 1:1 ratio of diastereoisomers. 
The trifluoroacetyl groups were rapidly cleaved from 11a and 11b with ammonia, giving the 
free sulfoximines 12a and 12b, respectively. Now, the individual diastereoisomers contained 
H-bond donors and thus the diastereoisomers could be separated chromatographically, giving 
good yields of stereochemically pure 12aR, 12aS, 12bR and 12bS. The acetal protection was 
removed by acid-catalysed hydrolysis from 12aR and from 12bR to give the homochiral diols 
13aR and 13bR, respectively, to demonstrate that the secondary alcohols could be revealed 
without loss of stereochemical integrity. However, simple examination of the 1-D 1H and 13C 
NMR spectra did not allow assignment of the configurations at sulfur of the dioxolanylmethyl 
sulfoximines 12 or of the diols 13. 
3. X-ray crystallography and solution conformation studies 
For each pair of diastereoisomeric sulfoximines 12a and 12b, one diastereoisomer was an oil 
but the other formed crystals (from ethanol / hexane) of quality suitable for X-ray crystallo-
graphic structure determination. The crystal structures (Figure 2) confirmed that both 
crystalline diastereoisomers were of S configuration at sulfur, i.e. that they were 12aS and 
12bS. 
Figure 2. X-ray crystal structures of 12aS and 
12bS with crystallographic numbering. 
12aS
12bS
The conformations of 12aS in solution in chloroform and in the crystal were compared with 
each other and with the solution conformation of the diastereoisomer 12aR. Similar comparis-
ons were made for the Ar-bromo analogues 12bS and 12bR. Since it may be postulated that 
the N-H of the sulfoximine may form an intramolecular H-bond with the adjacent dioxolane 
oxygen, forming 5/6-membered fused ring structures, MM2 energy-minimised structures 
were calculated for 12aR and 12aS with and without the constraints of these intramolecular 
H-bonds (Figure 3). The predicted conformations of the two diastereoisomers without the 
intramolecular H-bonds are very similar to each other. In contrast, the predicted intramolecul-
arly H-bonded conformation of 12aR is very crowded, with the 6-membered and 5-membered 
rings almost orthogonal, whereas that of 12aS is more open. In the predicted intramolecularly 
H-bonded conformation of 12aR, the dihedral angle between 4-H and 5-H of the dioxolane is 
ca. 90°; the observed 3J = 8.2 Hz coupling is inconsistent with such an angle. Thus 12aR is 
likely to adopt a conformation without an intramolecular H-bond in solution in chloroform, 
12aR no H-bond 12aS no H-bond
12aR with intramolecular H-bond 12aS with intramolecular H-bond
Figure 3. MM2 energy-minimised model structures of 12aR and 12aS without and with constraining intra-
molecular H-bond from sulfoximine N-H to O-1 of the dioxolane ring. Red, O; white, H; grey, C; blue, N; 
yellow, S. 
where this dihedral angle is ca. 165°. The predicted conformation of the diastereoisomer 12aS 
in the intramolecularly H-bonded structure has the five-membered dioxolane ring in a half-
chair and the six-membered ring in a twist-boat; this gives the dihedral angle between 4-H 
and 5-H as ca. 140°, whereas the corresponding angle in the non-H-bonded conformer is ca. 
165°. The observed coupling 3J = 7.9 Hz between these protons is consistent with both con-
formers. The NOESY spectrum of 12aS also did not distinguish between the possible con-
formers in chloroform but allowed assignment of the signals from the geminal dimethyl unit. 
There were cross-peaks between the 4-H signal and the upfield methyl signal at δ 1.21 and 
between the 5-H signal and the downfield methyl peak at δ 1.29, showing that the former 
singlet is due to the methyl cis to the 4-CH2OBn and the latter is due to the methyl trans to 
this substituent. The NMR spectra of the Ar-bromo analogues 12bR and 12bS were very 
similar, showing that the remote bromine had little effect on the conformations of the dia-
stereoisomers in solution. Overlap of some signals and poor resolution of some multiplets in 
the 1H NMR spectra of the deprotected derivatives 13aR and 13bR precluded any detailed 
analysis of their conformations in solution.  
The crystal structures of 12aS and 12bS (Figure 2) are remarkably similar and show extended 
conformations, with intermolecular H-bonding. In the structure of 12aS, the dihedral angle 
between the 4-CH2OBn and the 5-CH2SO(NH)Ph groups is 104°, corresponding to a half-
chair conformation for the five-membered ring. The former bulky substituent almost eclipses 
the 5-H and that the latter large group is close to eclipsing the 4-H. The methyl cis to the 5-
CH2SO(NH)Ph group is in the pseudo-axial position. The crowded 5-C—CH2S bond is in a 
staggered conformation, with the sulfoximine antiperiplanar to 4-C and gauche to the ring-
oxygen. Interestingly, the bond from the CH2 to the sulfoximine is also staggered but with the 
apparently bulky groups (Ph and dioxolane) almost gauche to each other (dihedral angle 81°). 
The structure of 12bS shows a slightly smaller dihedral angle between the 4-CH2OBn and the 
5-CH2SO(NH)Ph groups (97°) and the half-chair conformation of the dioxolane ring is dist-
orted. The eclipsing of the 4-H and 5-H by their vicinal substituents is correspondingly dimin-
ished. The methyl cis to the 5-CH2SO(NH)Ph group is again in the pseudo-axial position. The 
conformational arrangements of the two major side-chains are very similar to those in 12aS. 
As expected, the sulfoximine-sulfur atoms were approximately tetrahedral. The O=S=N bond 
angles in 12aS and 12bS were both 122°. Both compounds had S=N bond lengths of 1.52 Å 
and S=O bond lengths of 1.46 Å. 
4. Conclusions 
In this paper, we have reported the synthesis of two series of diastereoisomeric O-protected 4-
(arylsulfonimidoyl)butane-1,2,3-triols, deriving the configuration of the two secondary 
alcohols from diethyl R,R-tartrate. A Mitsunobu reaction introduced the arylthio substituents. 
Peroxyacid sulfoxidation proceeded without diastereocontrol and Rh-catalysed oxidative 
imination gave the corresponding N-trifluoroacetyl sulfoximines as inseparable mixtures of 
diastereoisomers at sulfur. Removal of the TFA protection afforded the free NH sulfoximines, 
which were readily separated chromatographically. The configurations of the crystalline S-S 
dioxolanes 12aS and 12bS were established by X-ray crystallography, for both the S-Ph and 
S-(3-BrAr) series. However, both corresponding S-R stereoisomers 12aR and 12bS were oils. 
Removal of the acetonide protection exposed the secondary alcohols in 13aR and 13bR. The 
homochiral O-protected 4-(arylsulfonimidoyl)butane-1,2,3-triols are of potential use in devel-
oping enzyme inhibitors. 
5. Experimental 
5.1. General. 
IR spectra were obtained on a Perkin-Elmer 782 Spectrometer as KBr discs or as liquid films. 
NMR spectra were recorded either on a Jeol EX270, Varian Mercury 400 or Varian United 
Inova 600 MHz spectrometers of samples in CDCl3, unless otherwise stated. Mass spectra 
were obtained by electrospray (ES), electron impact (EI) or fast atom bombardment (FAB) 
ionisation. Melting points were measured with a Thermo Galen Kofler block (uncorrected). 
Optical rotations were measured in a 1.0 dm cell on an Optical Activity Ltd. polarimeter and 
concentrations are expressed in g/100 mL. The chromatographic stationary phase was silica 
gel. THF refers to tetrahydrofuran, DMF refers to dimethylformamide. THF was dried with 
Na. Solutions in organic solvents were dried with MgSO4. Solvents were evaporated under 
reduced pressure. Experiments were conducted at ambient temperature, unless otherwise 
stated.  
5.2. 4S,5S-Di(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane (5).  
Diethyl (R,R)-2,3-dihydroxybutanedioate 4 (15.0 g, 70 mmol), 2,2-dimethoxypropane (32 g, 
320 mmol) and TsOH.H2O (198 mg, 1.0 mmol) in CH2Cl2 (200 mL) were boiled under reflux 
in a Soxhlet apparatus for 7 d through activated 4 Å molecular sieves (33 g). Dry Na2CO3 (83 
mg, 1.0 mmol) was added. Filtration, drying, evaporation and chromatography (EtOAc / 
hexane, 2:3) afforded a mixture of diethyl, monoethyl-monomethyl and dimethyl esters of 
(4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylic acid (12 g, ca. 67%) as a pale buff oil. 
LiAlH4 (2.0 M in THF, 51.5 mL, 103 mmol) was added during 1.5 h to this material in dry 
THF (80 mL) and the mixture was boiled under reflux for 5 h, then cooled to 0°C. Water (10 
mL), aq. NaOH (4 M, 10 mL) and water (30 mL) were added cautiously in turn. The 
suspension was filtered and the solids were extracted with boiling 1,4-dioxane (3 × 100 mL). 
The solvents were evaporated from the combined extracts to give 5 (6.7 g, 85%) as a pale 
yellow oil with spectroscopic data identical to those reported in the literature.14,18 
5.3. 4S,5S-Di(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane (6) and 4S,5S-4-benzyl-
oxymethyl-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane (7). 
NaH (60% in mineral oil, 1.9 g, 46 mmol, pre-washed with dry pentane) was stirred in dry 
DMF (20 mL) at 0°C under N2 for 30 min. Compound 5 (6.7 g, 42 mmol) in dry DMF (20 
mL) was then added dropwise and the mixture was stirred for 30 min before benzyl bromide 
(7.35 g, 43 mmol) was added. The mixture was stirred for 1.5 h and was poured into ice-water 
(250 mL) and extracted thrice with Et2O. The combined extracts were washed with water and 
brine. Drying, evaporation and chromatography (hexane / Et2O 1:1] gave 6 (500 mg, 6%) as a 
pale yellow oil with spectroscopic data identical to those reported in the literature.14 Further 
elution gave 7 (3.6 g, 71%) as a pale yellow oil with spectroscopic data identical to those 
reported in the literature.14 
5.4. 4S,5R-4-(Benzyloxymethyl)-5-(bromomethyl)-2,2-dimethyl-1,3-dioxolane (8). 
Ph3P (353 mg, 1.3 mmol) in dry THF (1.0 mL)was added dropwise to 7 (280 mg, 1.1 mmol) 
and CBr4 (409 mg, 1.2 mmol) in dry THF (2.0 mL) at 0°C under N2 and the mixture was 
stirred for 3 h. Evaporation and chromatography (hexane / Et2O, 1:1) gave 8 (240 mg, 69%) 
as a colourless oil: 1H NMR δ 1.43 (3 H, s, Me), 1.45 (3 H, s, Me), 3.46-3.54 (2 H, m, 
BrCH2), 3.62-3.69 (2 H, m, BnOCH2), 4.04-4.12 (2 H, m, 4,5-H2), 4.59 (2 H, s, PhCH2), 7.30-
7.38 (5 H, m, Ph-H5); 
13C NMR δ 27.1 (Me), 27.2 (Me), 32.6 (BrCH2), 70.4 (BnOCH2), 73.6 
(PhCH2), 77.2 (5-C), 78.8 (4-C), 110.0 (CMe2), 127.7 (Ph 3,5-C2), 127.8 (Ph 2,6-C2), 128.4 
(Ph 4-C), 137.7 (Ph 1-C); MS (FAB) m/z 317.0563 (M + H) (C14H20O3
81Br requires 
317.0575); 316.0503 (M) (C14H19O3
81Br requires 316.0497), 235 (M − Br), 220 (M − CH2Br); 
[α]20D = +3.6 (c 1.7, CHCl3). 
5.5. 4S,5R-4-(Benzyloxymethyl)-2,2-dimethyl-5-(phenylthiomethyl)-1,3-dioxolane (9a). 
PhSH (327 mg, 3.0 mmol) was added to Bu3P (601 mg, 3.0 mmol) and 1,1’-(azodicarbonyl)-
dipiperidine (749 mg, 2.97 mmol) in dry THF (7.0 mL) under Ar at 0°C and the mixture was 
sonicated for 30 min. During this sonication, 7 (500 mg, 2.0 mmol) in dry THF (3.0 mL) was 
added. The mixture was stirred at 20°C for 16 h. Filtration, evaporation and chromatography 
(hexane / Et2O 5:1) gave 9a (300 mg, 44%) as a pale yellow oil: 
1H NMR δ 1.40 (3 H, s, Me), 
1.44 (3 H, s, Me), 3.19 (1 H, d, J = 4.3 Hz, SCH), 3.20 (1 H, d, J = 4.3 Hz, SCH), 3.63 (2 H, 
d, J = 4.7 Hz, BnOCH2), 4.04-4.09 (2 H, m, 4,5-H2), 4.54 (1 H, d, J = 14.9 Hz, PhCH), 4.57 
(1 H, d, J = 14.9 Hz, PhCH), 7.16-7.36 (10 H, m, 2 × Ph-H5); 
13C NMR δ 27.1 (Me), 27.2 
(Me), 36.7 (SCH2), 70.7 (BnOCH2), 73.5 (PhCH2), 77.0 (5-C), 79.4 (4-C), 109.7 (CMe2), 
126.2 (Ph-C2), 127.8 (Ph-C2), 128.4 (Ph-C2), 128.9 (Ph-C2), 129.2 (2 × P 4-C), 135.8 (Ph 1-
C), 137.8 (Ph’ 1-C); MS (FAB) m/z 345.1522 (M + H) (C20H24O3S requires 345.1519), 329 
(M − CH3), 109 (PhSH), 91 (Bn); [α]
20
D = +4.4 (c 2.0, CHCl3).  
5.6. 4S,5R-4-(Benzyloxymethyl)-2,2-dimethyl-5-(3-bromophenylthiomethyl)-1,3-dioxol-
ane (9b). 
Compound 7 was treated with 3-bromothiophenol, as for the synthesis of 9a, to give 9b (69%) 
as a yellow oil. 1H NMR δ 1.39 (3 H, s, Me), 1.43 (3 H, s, Me), 3.16-3.19 (2 H, m, SCH2), 
3.59-3.66 (2 H, m, BnOCH2), 4.03-4.05 (2 H, m, 4,5-H2), 4.57 (2 H, s, PhCH2), 7.08 (1 H, t, J 
= 8.0 Hz, Ar 5-H), 7.22 (1 H, ddd, J = 8.1, 1.8, 1.0 Hz, Ar 6-H), 7.42-7.46 (5 H, m, Ph-H5), 
7.48-7.51 (2 H, m, Ar 2,4-H2); 
13C NMR δ 27.0 (Me), 27.1 (Me), 36.3 (SCH2), 70.5 
(BnOCH2), 73.6 (PhCH2), 77.2 (5-C), 79.1 (4-C), 110.0 (CMe2), 122.8 (Ar 3-C), 127.3 (CH), 
127.8 (Ph 3,5-C2), 128.4 (Ph 2,6-C2), 129.0 (Ph 4-C), 130.2 (Ar-CH), 131.2 (Ar-CH), 132.3 
(Ar-CH), 137.7 (Ph 1-C), 138.5 (Ar 1-C); [α]20D = +6.1 (c 2.5, CHCl3). 
5.7. 4S,5R,S(±)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(phenylsulfinylmethyl)-1,3-dioxol-
ane (10a). 
Compound 9a (180 mg, 0.52 mmol) was stirred with 3-chloroperoxybenzoic acid (111 mg, 
0.52 mmol) in CH2Cl2 (15 mL) at −78°C for 5 h. The mixture was washed (aq. NaHCO3, 
water). Drying and evaporation gave 10a (180 mg, 96%) as a 1:1 mixture of diastereoisomers 
as a pale yellow oil: IR νmax 1265 cm
-1; 1H NMR δ 1.37 (1.5 H, s, Me), 1.45 (1.5 H, s, Me), 
1.46 (1.5 H, s, Me), 1.47 (1.5 H, s, Me), 2.84 (0.5 H, dd, J = 13.2, 9.8 Hz, SCH (isomer A)), 
3.04 (0.5 H, dd, J = 13.2, 4.2 Hz, SCH (isomer B)), 3.06 (0.5 H, dd, J = 13.2, 2.2 Hz, SCH 
(isomer A)), 3.22 (0.5 H, dd, J = 13.2, 7.2 Hz, SCH (isomer B)), 3.51 (0.5 H, dd, J = 10.1, 5.7 
Hz, BnOCH (isomer B)), 3.55 (0.5 H, dd, J = 9.8, 5.7 Hz, BnOCH (isomer A)), 3.62 (0.5 H, 
dd, J = 9.8, 4.9 Hz, BnOCH (isomer B)), 3.68 (0.5 H, dd, J = 9.5, 5.3 Hz, BnOCH (isomer 
A)), 3.91 (0.5 H, dt, J = 5.3, 8.3 Hz, 4-H (isomer A)), 3.97 (0.5 H, m, 5-H (isomer B)), 4.15 
(0.5 H, dt, J = 5.3, 8.3 Hz, 4-H (isomer B)), 4.41 (0.5 H, ddd, J = 9.8, 8.3, 2.3 Hz, 5-H (isomer 
A)), 4.50 (0.5 H, d, J = 12.1 Hz, PhCH), 4.52 (0.5 H, d, J = 12.1 Hz, PhCH), 4.55 (1 H, s, 
PhCH2), 7.23-7.35 (5 H, m, Ph-H5), 7.50-7.53 (3 H, m, S-Ph 3,4,5-H3), 7.65-7.67 (2 H, m, S-
Ph 2,6-H2); 
13C NMR δ 26.8 (Me), 26.9 (Me), 27.0 (Me), 27.2 (Me), 60.2 (SCH2 (isomer B)), 
62.2 (SCH2 (isomer A)), 69.6 (BnOCH2 (isomer B)), 70.0 (BnOCH2 (isomer A)), 73.2 (5-C 
(isomer A)), 73.5 (PhCH2 (isomer B)), 73.7 (PhCH2 (isomer A)), 73.9 (5-C (isomer B)), 78.6 
(4-C (isomer B)), 79.0 (4-C (isomer A)), 110.0 (CMe2), 110.2 (CMe2), 123.8 (CH), 124.3 
(CH), 127.6 (CH), 127.7 (CH), 127.8 (CH), 128.4 (CH), 129.2 (CH), 129.3 (CH), 131.2 (S-Ph 
4-CH), 131.3 (S-Ph 4-CH), 137.6 (C-Ph 1-C), 137.7 (C-Ph 1-C), 143.5 (S-Ph 1-C (isomer B)), 
144.5 (S-Ph 1-C (isomer A)); MS (FAB) m/z 361 (M + H), 303 (M + H − Me2CO); [α]
20
D = 
+4.4 (c 2.0, CHCl3). 
5.8. 4S,5R,S(±)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(3-bromophenylsulfinylmethyl)-1,3-
dioxolane (10b). 
Compound 9b was treated with 3-chloroperoxybenzoic acid, as for the synthesis of 10a, to 
give 10b (68%) as a 3:2 mixture of diastereoisomers as a yellow oil: 1H NMR δ 1.16 (1.8 H, 
Me), 1.21 (1.2 H, Me), 1.25 (1.8 H, Me), 1.26 (1.2 H, Me), 3.42 (dd, J = 9.6, 6.8 Hz) and 3.43 
(dd, J = 9.7, 6.8 Hz) (BnOCHH), 3.65 (dd, J = 10.7, 4.7 Hz) and 3.66 (dd, J = 10.2, 4.7 Hz) 
(BnOCHH), 3.79 (dd, J = 14.1, 8.6 Hz) and 3.81 (dd, J = 14.4, 9.7 Hz) (SCHH), 3.86-3.92 (1 
H, m, 4-H), 3.99 (dd, J = 11.2, 2.3 Hz) and 4.03 (dd, J = 11.2, 2.2 Hz (SCHH), 4.14-4.19 (1 
H, m, 5-H), 4.49 (2 H, s, PhCH2), 7.23-7.37 (5 H, m, Ph-H5), 7.54-7.60 (2 H, m, S-Ph 3,5-H2), 
7.70 (1 H, t, J = 8 Hz, S-Ph 4-H), 7.94 (2 H, d, J = 8 Hz, S-Ph 2,6-H2); 
13C NMR δ 26.4 (Me), 
26.6 (Me), 58.5 (SCH2), 59.3 (SCH2), 69.6 (BnOCH2), 69.7 (BnOCH2), 72.9 (5-C), 73.3 (5-
C), 73.6 (PhCH2), 73.7 (PhCH2), 78.1 (4-C), 78.2 (4-C), 110.8 [CMe2], 127.7 (CH), 127.8 
(CH), 127.9 (C-Ph 2,6-C2), 128.0 (CH), 128.2 (S-Ph 2,6-C2), 128.3 (CH), 128.47 (CH), 
128.49 (CH), 128.53 (C-Ph 3,5-C2), 129.0 (CH), 129.5 (S-Ph 3,5-C2), 134.6 (S-Ph 4-C), 134.8 
(S-Ph 4-C), 135.3 (S-Ph 1-C), 135.4 (S-Ph 1-C), 137.32 (C-Ph 1-C), 137.35 (C-Ph 1-C); 19F 
NMR δ −76.0 (1.8 F, s), −75.9 (1.2 F, s); [α]20D = +3.7 (c 2.0, CHCl3). 
5.9. 4S,5R,S(±)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(N-(trifluoroacetyl)phenylsulfonim-
idoylmethyl)-1,3-dioxolane (11a). 
PhI(OAc)2 (242 mg, 0.75 mmol) was stirred vigorously with 10a (180 mg, 0.5 mmol), 
CF3CONH2 (113 mg, 1.0 mmol), MgO (81 mg, 2.0 mmol) and Rh2(OAc)4 (5.5 mg, 2.5 
mol%) in CH2Cl2 (10 mL) for 6 d. Filtration (Celite
®), evaporation and chromatography 
(hexane / Et2O, 1:1) afforded 11a (176 mg, 75%) as a 3:2 mixture of diastereoisomers as a 
pale yellow oil: IR νmax 1422, 1265, 1173 cm
-1; 1H NMR δ 1.16 (1.8 H, Me), 1.21 (1.2 H, 
Me), 1.25 (1.8 H, Me), 1.26 (1.2 H, Me), 3.42 (dd, J = 9.6, 6.8 Hz) and 3.43 (dd, J = 9.7, 6.8 
Hz) (BnOCHH), 3.65 (dd, J = 10.7, 4.7 Hz) and 3.66 (dd, J = 10.2, 4.7 Hz) (BnOCHH), 3.79 
(dd, J = 14.1, 8.6 Hz) and 3.81 (dd, J = 14.4, 9.7 Hz) (SCHH), 3.86-3.92 (1 H, m, 4-H), 3.99 
(0.5 H, dd, J = 11.2, 2.3 Hz, SCH) and 4.03 (0.5 H, dd, J = 11.2, 2.2 Hz, SCH), 4.14-4.19 (1 
H, m, 5-H), 4.49 (2 H, s, PhCH2), 7.23-7.37 (5 H, m, Ph-H5), 7.54-7.60 (2 H, m, S-Ph 3,5-H2), 
7.70 (1 H, t, J = 8 Hz, S-Ph 4-H), 7.94 (2 H, d, J = 8 Hz, S-Ph 2,6-H2); 
13C NMR δ 26.4 (Me), 
26.6 (Me), 58.5 (SCH2), 59.3 (SCH2), 69.6 (BnOCH2), 69.7 (BnOCH2), 72.9 (4-C), 73.3 (4-
C), 73.6 (PhCH2), 73.7 (PhCH2), 78.1 (5-C), 78.2 (5-C), 110.8 (CMe2), 127.7 (Ph-CH), 127.8 
(Ph-CH), 127.9 (C-Ph 2,6-C2), 128.0 (Ph-CH), 128.2 (S- Ph 2,6-C2), 128.3 (Ph-CH), 128.47 
(Ph-CH), 128.49 (Ph-CH), 128.53 (C-Ph 3,5-C2), 129.0 (Ph-CH), 129.5 (S- Ph 3,5-C2), 134.8 
(Ph 1-C), 135.3 (Ph 1-C), 135.4 (Ph 1-C), 138.0 (Ph 1-C); 19F NMR δ −76.0 (1.8 F, s), −75.9 
(1.2 F, s); MS (FAB) m/z 472.1382 (M + H) (C22H25NO5F3S requires 472.1406), 472 (M + H 
− O), 414 (M + H − Me2CO); [α]
20
D = +5.1 (c 2.6, CHCl3). 
5.10. 4S,5R,S(±)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(N-trifluoroacetyl-3-bromophenyl-
sulfonimidoylmethyl)-1,3-dioxolane (11b). 
Compounds 10b were treated with trifluoroacetamide, PhI(OAc)2 and Rh2(OAc)4, as for the 
synthesis of 11a, to give 11b (83%) as a 1:1 mixture of diastereoisomers as a pale yellow oil: 
IR νmax 1746, 1216, 1176 cm
-1; 1H NMR δ 1.15 (1.5 H, s, Me), 1.21 (1.5 H, s, Me), 1.26 (1.5 
H, s, Me), 1.28 (1.5 H, s, Me), 3.49 (1 H, m, BnOCH), 3.66 (0.5 H, dd, J = 8.2, 4.8 Hz, 
BnOCH), 3.68 (0.5 H, dd, J = 8.2, 4.8 Hz, BnOCH), 3.70-3.75 (0.5 H, m, SCH), 3.76 (0.5 H, 
dd, J = 14.6, 9.8 Hz, SCH), 3.87 (1 H, m, 4-H), 4.05 (0.5 H, dd, J = 10.0, 2.2 Hz, SCH), 4.09 
(0.5 H, dd, J = 9.9 Hz, 2.3 Hz, SCH), 4.14-4.22 (1 H, m, 5-H), 4.51 (2 H, s, PhCH2), 7.27-
7.40 (5 H, m, Ph-H5), 7.43 (1 H, dt, J = 1.9, 8.0 Hz, Ar 5-H), 7.72-7.85 (2 H, m, Ar 4,6-H2), 
8.08 (0.5 H, t, J = 1.6 Hz, Ar 2-H), 8.11 (0.5 H, t, J = 1.9 Hz, Ar 2-H); 13C NMR δ 26.4 (Me), 
26.5 (Me), 26.6 (Me), 58.6 (SCH2), 59.4 (SCH2), 69.5 (BnOCH2), 69.6 (BnOCH2), 72.9 (5-
C), 73.4 (5-C), 73.8 (PhCH2), 77.97 (4-C), 78.02 (4-C), 110.8 (CMe2), 110.9 (CMe2), 123.3 
(Ar 3-C), 126.7, 126.8, 127.8, 128.0, 128.1, 128.5, 128.6, 130.83 (Ar 5-C), 130.85 (Ar 5-C), 
131.3 (Ar 2-CH), 131.4 (Ar 2-C), 137.2 (Ph 1-C), 137.3 (Ph 1-C), 137.4 (Ar 1-C), 137.5 (Ar 
1-C), 137.7, 137.8; 19F NMR δ −76.0 (1.5 F, s, CF3), −75.9 (1.5 F, s, CF3); [α]
20
D = +4.3 (c 
1.4, CHCl3). 
5.11. 4S,5R,S(R)-(Benzyloxymethyl)-2,2-dimethyl-5-(phenylsulfonimidoylmethyl)-1,3-di-
oxolane (12aR) and 4S,5R,S(S)-4-(benzyloxymethyl)-2,2-dimethyl-5-(phenylsulfonimid-
oylmethyl)-1,3-dioxolane (12aS). 
Compounds 11a (176 mg, 0.37 mmol) were stirred with NH3 (35% in water, 2.0 mL) in 
MeOH (5.0 mL) for 16 h. Evaporation and chromatography (EtOAc / hexane, 2:3) yielded 
12aR (42 mg, 30%) as a pale yellow oil: IR νmax 3332, 733 cm
-1; 1H NMR δ 1.33 (3 H, s, 
Me), 1.37 (3 H, s, Me), 3.10 (1 H, br s, NH), 3.30 (1 H, dd, J = 13.6, 8.7 Hz, SCH), 3.45 (1 H, 
dd, J = 13.6, 2.9 Hz, SCH), 3.53 (1 H, dd, J = 9.8, 5.8 Hz, BnOCH), 3.67 (1 H, dd, J = 9.8, 
5.3 Hz, BnOCH), 3.90 (1 H, dt, J = 7.7, 5.3 Hz, 4-H), 4.45 (1 H, dt, J = 2.9, 8.7 Hz, 5-H), 
4.51 (2 H, s, PhCH2), 7.27-7.35 (5 H, m, Ph-H5), 7.50 (2 H, m, S-Ph 3,5-H2), 7.59 (1 H, m, S-
Ph 4-H), 8.00 (2 H, m, S-Ph 2,6-H2); 
13C NMR δ 26.8 (Me), 26.9 (Me), 61.3 (SCH2), 70.0 
(BnOCH2), 73.6 (PhCH2), 73.7 (5-C), 78.7 (4-C), 110.4 (CMe2), 127.6 (Ph 3,5-C2), 127.7 (Ph 
4-C), 128.4 (Ph 3,5-C2), 128.5 (Ph 2,6-C2), 129.0 (Ph 2,6-C2), 133.1 (Ph 4-C), 137.6 (Ph 1-C), 
141.5 (Ph 1-C); MS (FAB) m/z 376 (M + H); MS (ES) m/z 775 (2 M + Na), 399 (M + Na), 
375 (M); [α]20D = +8.4 (c 2.3, CHCl3). Further elution gave 12aS (47 mg, 34%) as a white 
solid: mp 86-88°C; IR νmax 3332, 734 cm
-1; 1H NMR δ 1.21 (3 H, s, Me trans to CH2OBn), 
1.29 (3 H, s, Me cis to CH2OBn), 3.39 (1 H, dd, J = 14.2, 8.2 Hz, SCH), 3.50-3.54 (2 H, m, 
SCH + BnOCH), 3.64 (1 H, dd, J = 9.7, 5.3 Hz, BnOCH), 3.93 (1 H, dt, J = 7.6, 5.3 Hz, 4-H), 
4.31 (1 H, dt, J = 3.4, 8.2 Hz, 5-H), 4.51 (2 H, s, PhCH2), 7.26-7.35 (5 H, m, Ph-H5), 7.48 (2 
H, m, S-Ph 3,5-H2), 7.58 (1 H, m, S-Ph 4-H), 7.96 (2 H, m, S-Ph 2,6-H2); 
13C NMR δ 26.7 
(Me), 26.8 (Me), 61.0 (SCH2), 69.9 (BnOCH2), 73.5 (5-C), 73.6 (PhCH2), 78.6 (4-C), 110.1 
(CMe2), 127.6 (Ph 3,5-C2), 127.7 (Ph 4-C), 128.4 (Ph 3,5-C2), 128.5 (Ph 2,6-C2), 128.8 (Ph 
2,6-C2), 133.0 (Ph 4-C), 137.6 (Ph 1-C), 141.5 (Ph 1-C); MS (FAB) m/z 376 (M + H); [α]
20
D 
= +7.8 (c 2.3, CHCl3). 
5.12. 4S,5R,S(R)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(3-bromophenylsulfonimidoyl-
methyl)-1,3-dioxolane (12bR) and 4S,5R,S(S)-4-(benzyloxymethyl)-2,2-dimethyl-5-(3-
bromophenylsulfonimidoylmethyl)-1,3-dioxolane (12bS). 
Compounds 11b were treated with NH3, as for the synthesis of 12aR and 12aS except that the 
chromatographic eluant was EtOAc / hexane (7:3), to give 12bR (29%) as a pale yellow oil: 
1H NMR δ 1.22 (3 H, s, Me), 1.32 (3 H, s, Me), 3.34 (1 H, dd, J = 14.5, 9.0 Hz, SCH), 3.46 (1 
H, dd, J = 14.5, 2.7 Hz, SCH), 3.52 (1 H, dd, J = 9.8, 6.3 Hz, BnOCH), 3.69 (1 H, dd, J = 9.8, 
5.1 Hz, BnOCH), 3.86 (1 H, ddd, J = 7.8, 6.3, 4.7 Hz, 4-H), 4.31 (1 H, ddd, J = 8.6, 7.8, 2.7 
Hz, 5-H), 4.53 (2 H, s, PhCH2), 7.29-7.37 (5 H, m, Ph-H5), 7.38 (1 H, t, J = 7.8 Hz, Ar 5-H), 
7.75 (1 H, ddd, J = 7.8, 2.0, 0.8 Hz, Ar 4-H or Ar 6-H), 7.82 (1 H, ddd, 7.8, 2.0, 0.8 Hz, Ar 6-
H or Ar 4-H), 8.08 (1 H, t, J = 1.9 Hz, Ar 2-H); 13C NMR δ 26.7 (Me), 26.8 (Me), 59.7 
(SCH2), 69.9 (BnOCH2), 73.6 (5-CH), 73.7 (PhCH2), 78.4 (4-C), 110.3 [CMe2], 122.8 (Ar 3-
C), 126.9, 127.7, 127.9, 128.5, 130.4, 131.6, 136.7, 137.5 (Ph 1-C), 141.6 (Ar 1-C); MS (ES) 
m/z 456.0642 (M + H) (C20H25
81BrNO4S requires 456.0668), 455.0585 (M) (C20H24
81BrNO4S 
requires 456.0590), 454.0669 (M + H) (C20H25
79BrNO4S requires 454.0682), 453.0604 (M) 
(C20H24
79BrNO4S requires 453.0610); [α]
20
D = +3.2 (c 1.5, CHCl3). Further elution gave 12bS 
(32%) as a white solid: mp 75-77°C; 1H NMR δ 1.20 (3 H, s, Me), 1.31 (3 H, s, Me), 2.32 (1 
H, br s, NH), 3.38 (1 H, dd, J = 14.3, 8.7 Hz, SCH), 3.52 (1 H, dd, J = 9.5, 6.3 Hz, BnOCH), 
3.54 (1 H, dd, J = 14.3, 3.0 Hz, SCH), 3.66 (1 H, dd, J = 9.5, 5.1 Hz, BnOCH), 3.89 (1 H, 
ddd, J = 8.0, 6.3, 5.1 Hz, 4-H), 4.33 (1 H, ddd, J = 8.5, 8.0, 2.9 Hz, 5-H), 4.53 (2 H, s, 
PhCH2), 7.27-7.39 (5 H, m, Ph-H5), 7.36 (1 H, t, J = 8.0 Hz, Ar 5-H), 7.70 (1 H, ddd, J = 8.0, 
2.1, 1.0 Hz, Ar 4-H or Ar 6-H), 7.90 (1 H, ddd, J = 8.0, 2.1, 1.0 Hz, Ar 6-H or Ar 4-H), 8.14 
(1 H, t, J = 1.9 Hz, Ar 2-H); 13C NMR δ 26.7 (Me), 26.8 (Me), 61.0 (SCH2), 69.9 (BnOCH2), 
73.7 (PhCH2 + 5-C), 78.4 (4-C), 110.3 [CMe2], 122.7 (Ar 3-C), 127.2, 127.7 (Ph 3,5-C2), 
127.9, 128.5 (Ph 2,6-C2), 130.3 (Ar 5-C), 131.8 (Ar 2-C), 136.0, 137.5 (Ph 1-C), 144.3 (Ar 1-
C); Anal. Calcd. for C20H24BrNO4S: C, 52.87; H, 5.32; N, 3.08. Found: C, 52.82; H, 5.22; N, 
3.06; [α]20D = +2.6 (c 1.5, CHCl3). 
5.13. 2S,3R,S(R)-1-(Benzyloxy)-4-(phenylsulfonimidoyl)butane-2,3-diol (13aR). 
Compound 12aR (38 mg, 0.1 mmol) was stirred with aq. HCl (9 M, 1.0 mL) in MeOH (5.0 
mL) for 4 h. Evaporation and chromatography (EtOAc / MeOH, 7:3) afforded 13aR (37 mg, 
100%) as a pale yellow oil: IR νmax 3305 cm
-1; 1H NMR δ 2.68 (1 H, br, OH), 3.13 (1 H, dd, J 
= 13.8, 1.7 Hz, SCH), 3.45 (1 H, dd, J = 13.8, 10.1 Hz, SCH), 3.59-3.63 (2 H, m, BnOCH2), 
3.69 (1 H, m, 3-H), 4.54-4.56 (3 H, m, PhCH2 + 4-H), 7.27-7.35 (5 H, m, Ph-H5), 7.56 (2 H, 
m, S-Ph 3,5-H2), 7.64 (1 H, m, S-Ph 4-H), 7.98 (2 H, m, S-Ph 2,6-H2); 
13C NMR δ 59.8 
(SCH2), 66.4 (4-C), 71.0 (1-C), 72.4 (3-C), 73.5 (PhCH2), 127.7 (Ph 3,5-C2), 127.8 (Ph 4-C), 
128.1 (Ph 3,5-C2), 128.5 (Ph 2,6-C2), 129.4 (Ph 2,6-C2), 133.5 (Ph 4-C), 137.7 (Ph 1-C), 
142.6 (Ph 1-C); MS (FAB) m/z 336 (M + H); MS (ES+) m/z 693 (2 M + Na), 671 (2 M + H), 
336.1264 (M + H) (C17H23NO4S requires 336.1264); MS (ES−) m/z 372/370 (M + Cl); MS 
(EI) m/z 336 (M + H), 244 (M − Bn), 214 (M − BnOCH2), 91 (Bn); [α]
20
D = +5.5 (c 1.3, 
CHCl3). 
5.14. 2S,3R,S(R)-1-(Benzyloxy)-4-(3-bromophenylsulfonimidoyl)butane-2,3-diol (13bR). 
Compound 12bR was treated with aq. HCl, as for the synthesis of 13aR, to give 13bR (100%) 
as a pale yellow solid: mp 73-76°C; IR νmax 3425 cm
-1; 1H NMR δ 3.00 (2 H, br, 2 ×OH), 3.13 
(1 H, d, J = 14 Hz, SCH), 3.45 (1 H, dd, J = 13.9, 10.1 Hz, SCH), 3.59-3.64 (2 H, m, 
BnOCH2), 3.70 (1 H, m, 2-H), 4.52 (1 H, d, J = 11.7 Hz, PhCH), 4.54 (1 H, d, J = 11.7 Hz, 
PhCH), 4.55 (1 H, br d, J = 10 Hz, 3-H), 7.27-7.36 (5 H, m, Ph-H5), 7.43 (1 H, t, J = 7.9 Hz, 
Ar 5-H), 7.75 (1 H, ddd, J = 8.0, 1.9, 0.8 Hz, Ar 4-H or Ar 6-H), 7.91 (1 H, ddd, J = 8.0, 1.9, 
0.8 Hz, Ar 6-H or Ar 4-H), 8.12 (1 H, t, J = 1.8 Hz, Ar 2-H); 13C NMR δ 59.9 (SCH2), 66.5 
(3-C), 71.0 (1-C), 72.3 (2-C), 73.6 (PhCH2), 123.4 (Ar 3-C), 126.7, 127.9 (Ph 3,5-C2), 128.0, 
128.6 (Ph 2,6-C2), 130.9, 131.1, 136.7, 137.6 (Ph 1-C), 141.0 (Ar 1-C); Anal. Calcd. for 
C17H20BrNO4S: C, 49.28; H, 4.87; N, 3.38. Found: C, 49.48; H, 4.61; N, 2.95; [α]
20
D = +2.5 
(c 1.7, CHCl3). 
5.15. Crystal data for 12aS. 
Crystals of quality suitable for X-ray crystallography were grown from EtOH / hexane. 
C20H25NO4S, M = 375.47, orthorhombic, a = 5.5540(1), b = 18.4970(3), c = 19.2410(4) Å, U 
= 1976.67(6)Å3, T = 150(2) K, space group = P212121, Z = 4, µ(Mo-Kα) = 0.188 mm
-1, 4490 
reflections (Rint = 0.04977), R1 = 0.03581 and wR2 = 0.0772 based on 3837 F
2 with Fo = > 
4σ(Fo). Software used: Software used: SHELXS,
19 SHELXL-9720 and ORTEX.21 Atoms 
C14-C20 disordered in 1:1 ratio with C14A-C20A, respectively. H1 located and refined at 
0.89 Å from N1. CCDC 654427. 
5.16. Crystal data for 12bS. 
Crystals of quality suitable for X-ray crystallography were grown from EtOH / hexane. 
C20H24NO4SBr, M = 454.37, monoclinic, a = 12.3520(2), b = 5.5440(1), c = 15.7540(3) Å, β 
= 103.459(1)o, U = 1049.20(3)Å3, T = 150(2) K, space group = P21, Z = 2, µ(Mo-Kα) = 2.083 
mm-1, 5447 reflections (Rint = 0.0506), R1 = 0.0347 and wR2 = 0.0731 based on 4752 F
2 with 
Fo = > 4σ(Fo). Software used: SHELXS,
19 SHELXL-9720 and ORTEX.21 H1 located and 
refined at 0.89 Å from N1. CCDC 654428. 
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